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Abstract 
Background & Aims: There are few data from longitudinal studies of the gastrointestinal and 
psychologic features of irritable bowel syndrome (IBS). We studied within-person correlations among 
features of IBS, along with progression of gastrointestinal (GI) symptoms and quality of life, and 
factors associated with changes over time. 
Methods: We performed a longitudinal study of 276 patients with IBS in Sweden (70% female; ages, 
19–76 years) who completed questionnaires, each year for 5 years, about their GI symptom severity, 
quality of life, GI-specific anxiety, general anxiety, depression, and coping resources. We performed 
within-person correlation analyses, latent class growth analysis, and random-intercept cross-lagged 
panel analysis. 
Results: Within-person correlations with GI symptom severity were strongest for quality of life (r=–
0.56) and GI-specific anxiety (r=0.47). Progression of GI symptom severity was defined based on 3 
classes; the class with the highest mean levels of GI, depression, and (GI-specific) anxiety symptoms 
at baseline did not improve over the 5-year period, contrary to the other classes. GI-specific anxiety 
was associated with an increase in GI symptom severity and decrease in quality of life 1 year later 
(P<.05) but other features of IBS were not. 
Conclusions: In a 5-year study of patients with IBS in Sweden, we found 3 classes of GI symptom 
development. We found levels of GI-specific anxiety to associate with GI symptom severity and 
quality of life 1 year later. Clinicians should be aware of GI-specific anxiety in patients with IBS, to 
identify patients at risk for lack of long-term symptom improvement with standard medical 
treatment. 
Keywords: functional gastrointestinal disorders; natural evolution; prediction; prognostic factor 
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Introduction 
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder (FGID) defined 
by chronic and/or recurrent abdominal pain associated with altered bowel habits.
1
 However, IBS 
patients frequently suffer from psychological symptoms as well.
2
 IBS prevalence is roughly 10%,
3
 and, 
unfortunately, treatment and clinical management remains suboptimal.
4
 
IBS symptoms are thought to wax and wane, without being progressive in the long term. Some 
studies have followed up IBS patients over several years, showing that the IBS diagnosis is often not 
continuously present over time,
5
 and that symptom severity fluctuates substantially.
6, 7
 Others found 
that improvements in symptom severity after three months predicted improvement after one year,
8
 
possibly indicating some consistency in symptom evolution. Improvement was also predicted by 
anxiety/depression at baseline. This seems counterintuitive, but may be an effect of regression-to-
the-mean; patients with severe symptoms at baseline are more likely to improve on average whereas 
those with mild symptoms are more likely to worsen. Finally, one study reported that in individuals 
without IBS at baseline, anxiety levels predicted the onset of IBS at a follow-up of twelve years, while 
in individuals without anxiety at baseline, IBS predicted an increase in anxiety.
9
 In summary, the 
evolution of IBS over time is complex and longitudinal studies are scarce and inconsistent, with a 
possible but uncertain role for psychological features, in line with the Rome IV conceptualization of 
FGIDs as disorders of gut-brain interactions.
10
 
Further, most of the few published longitudinal IBS studies relied on two data points, whereas more 
data points are desirable to study symptom evolution. Besides, several psychological features have a 
cross-sectional association with IBS, such as GI-specific anxiety and coping resources,
11, 12
 but their 
longitudinal relation with IBS symptom severity has not been investigated. Finally, IBS patients are 
heterogeneous, and results may render more meaningful on the within-person or subgroup level 
than on the between-person or total sample level. We therefore investigate: 1) longitudinal within-
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person correlations of IBS features, and 2) evolution of GI symptoms and quality of life, subgroups 
thereof, and predictors of their changes over time. 
 
Methods 
 
IBS cohort 
 
Patients 
We used a Swedish longitudinal cohort of 276 adult IBS patients (≥ 18 years old), who were referred 
to our specialised unit for FGIDs from primary care or through self-referral. During an interview, the 
medical history was recorded and the diagnosis was made according to Rome II criteria, based on 
clinical presentation and additional investigations if considered necessary by the gastroenterologist 
(MS). However, the vast majority of patients who were referred from primary care had already 
undergone sufficient investigations to rule out other diagnoses with reasonable certainty. All patients 
were included in different studies assessing the pathophysiology of IBS,
13-17
 although not in studies 
testing a standardised treatment. Exclusion criteria were abnormal results on standard screening 
laboratory tests, severe psychiatric, systemic, or other GI diseases, allergies, history of drug or alcohol 
abuse, and the inability to respond to questionnaires in Swedish. All patients gave written consent to 
participate after verbal and written information. The study protocol was approved by the Regional 
Ethical Review Board in Gothenburg prior to enrolment. 
 
Questionnaires 
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Participants completed questionnaires once annually over five years, covering the following IBS 
features: GI symptom severity (Gastrointestinal Symptom Rating Scale, GSRS,
18
 scale: 1 to 7), which 
queries the subdomains diarrhoea, constipation, abdominal pain, satiety, indigestion, and reflux; 
quality of life (IBS-QOL,
19
 scale: 0 to 100), which specifically assesses the effect of IBS on quality of 
life; GI-specific anxiety (Visceral Sensitivity Index, VSI,
20
 scale: 0 to 75), which queries fear and anxiety 
for GI symptoms as endogenous stressor; general anxiety and depression (Hospital Anxiety and 
Depression scale, HADS,
21
 scale: 0 to 21); coping resources (Coping Resources Inventory, CRI,
22
 scale: 
60 to 240), which queries the way in which people handle stress in its broadest sense. 
 
Other measures 
At the start of the study, demographic information was collected, and all patients were subtyped 
based on the Rome II recommendation.
23
 We also recorded if the onset of IBS occurred after a 
gastroenteritis, i.e. post-infectious IBS (PI-IBS). Participants underwent a barostat protocol, in which a 
balloon was distended in the rectum with 5 mmHg increments until the first report of pain (details 
elsewhere
24
). Finally, we quantified oroanal transit time (OATT) in a one-week protocol, where 
participants ingested ten radiopaque rings every morning, and on the seventh day the rings 
remaining in the bowel were counted (details elsewhere
16
). This number was divided by the number 
of rings per day to obtain OATT in days. A normal transit time was defined as 0.7–2.2 days for men 
and 0.9–4.2 days for women.
25
 
 
Data analysis 
 
Longitudinal within-person correlations of IBS features 
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We used R version 3.3.3
26
 to compute within-person correlations between IBS features. Within-
person correlations differ from regular Pearson correlations, which may miss processes relevant to 
the individual as exemplified in Supplementary Figure 1. Within-person correlations were computed 
by, for each participant, centering values on zero prior to computing regular Pearson correlations. 
Within-person correlations were visualised in a network using the R-package qgraph
27
. 
 
Symptom evolution and subgroups thereof 
We used Mplus version 7.4
28
 to perform two separate latent class growth analyses of GI symptom 
severity and quality of life. Simply put, this analysis searches for patient subgroups with common 
symptom evolution trajectories (i.e. "classes"). It does so based on overall severity level ("intercept"), 
linear development over time ("linear slope"), and u-shaped developments ("quadratic coefficients"). 
Technically, the number of latent trajectory classes was determined by the minimum Bayesian 
Information Criterion (BIC), given a statistically significant Lo-Mendell-Rubin adjusted test. Missing 
data was handled using the full information maximum likelihood (FIML) procedure. 
We compared the classes by several baseline characteristics: age, sex, IBS subtype, PI-IBS status, 
rectal pain threshold, OATT, GI symptom severity, quality of life, GI-specific anxiety, general anxiety, 
depression, and coping resources. These comparisons were done using analysis of variance, Kruskal-
Wallis, or chi-square tests as appropriate. 
 
Prediction of rank order changes in GI symptom severity and quality of life 
We used the R-package lavaan
29
 to create so-called random-intercept cross-lagged panel models of 
psychological IBS features on the one hand (i.e. GI-specific anxiety, coping resources, general anxiety, 
and depression), and IBS outcomes on the other (i.e. GI symptom severity and quality of life). Simply 
put, these models analyse predictive relations between two variables. For example, it tests whether 
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anxiety at year 0 predicts GI symptom severity at year 1 while controlling for GI symptom severity at 
year 0. More formally, the technique is from structural equation modelling and investigates lagged 
associations while controlling for auto-regressive and within-time associations. The technique has 
been used particularly in social science to assess the directionality of effects (e.g. 
30
). Here we 
selected a cross-lagged model that specifically accounts for heterogeneity.
31
 Missing data was 
handled using the FIML procedure. 
 
Results 
 
IBS cohort 
Of the 276 participants, 70% were female, and the age ranged from 19 to 76 years (median 39). All 
IBS features except coping resources had improving sample averages over the years, and all IBS 
features had some within-person variation (for example, the median within-person range of all IBS 
features was greater than one sample standard deviation). Descriptive statistics are in table 1. We 
compared participants who completed the study to those who dropped out (last available data point 
was used), and there were no statistically significant differences in any IBS feature (Supplementary 
Table 1). 
 
Longitudinal within-person correlations of IBS features 
GI symptom severity had strong within-person correlations with quality of life (r=-0.56, p<0.001) and 
GI-specific anxiety (r=0.47, p<0.001). By contrast, GI symptom severity had weaker within-person 
correlations with all other psychological variables: depression (r=0.26, p<0.001), general anxiety 
(r=0.22, p<0.001), and coping resources (r=-0.15, p=0.02). A network is shown in figure 1, with the 
full correlation matrix in table 2. 
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Symptom evolution and subgroups thereof 
GI symptom severity evolved by three classes, representing 59, 119, and 36 IBS patients, respectively. 
The classes differed by overall baseline severity (i.e. intercept, p<0.001), and represent low, 
intermediate, or high GI symptom severity. To a lesser extent, there was also a difference in slope 
(p=0.002, i.e. the high GI symptom severity class did on average not improve, whereas the low and 
intermediate GI symptom severity classes did). The high GI symptom severity class was characterised 
by the youngest age (p=0.004), largest share of women (p=0.001), smallest share of PI-IBS (p=0.04), 
lowest rectal pain threshold at baseline (p=0.002), and the worst baseline score on all psychological 
IBS features except coping resources. Statistics are listed in table 3. 
Quality of life evolved by four classes, representing 24, 43, 73, and 67 IBS patients, respectively. The 
classes differed by overall baseline level (i.e. intercept, p<0.001), and represent low, intermediate 
(2x), and high quality of life. The classes did not differ in evolution over time. The low quality of life 
class had the lowest rectal pain threshold at baseline (p=0.002) and the worst baseline scores on all 
psychological IBS features. Statistics are listed in table 3, and the trajectory classes are visualised in 
figure 2. The entropies of the two trajectory class solutions were 0.81 and 0.79, respectively. 
 
Prediction of changes in GI symptom severity and quality of life 
GI-specific anxiety predicted a change in both GI symptom severity (increase, p=0.031) and quality of 
life (decrease, p=0.050) one year later. Quality of life also predicted a change in GI-specific anxiety 
one year later (p=0.026). However, coping resources, general anxiety, and depression did not predict 
a change in either outcome. Random-intercept cross-lagged panel models are shown in figure 3, in 
which diagonal paths between variables are of particular interest, as they represent predictive 
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relations, whereas horizontal and vertical paths represent stability coefficients, within-time 
correlations, or correlated change. 
 
Discussion 
 
In this study, we show that GI symptom severity has strong within-person correlations with GI-
specific anxiety and quality of life, but not with the other psychological IBS features. We further show 
that GI symptom severity is described by different trajectory classes. The class with the highest GI 
symptom severity on average did not improve over a five-year period. This class had, compared to 
the classes of low and intermediate GI symptom severity, the worst baseline scores on various 
psychological features and the lowest rectal pain threshold, and there was a high proportion of 
women but a low number of PI-IBS patients. Finally, we show that GI-specific anxiety can predict an 
increase in GI symptom severity, and decrease in quality of life one year later. 
 
Longitudinal within-person correlations of IBS features 
GI symptom severity had strong longitudinal within-person correlations with quality of life and GI-
specific anxiety, but only weak correlations with the other psychological IBS features. The key 
message is thus twofold: first, GI-specific anxiety is positioned as a feature closely related to GI 
symptom severity. Second, general anxiety, depression, and coping resources are only weakly related 
to GI symptom severity on the within-person level, so that these psychological features and GI 
symptom severity are likely to stand in relative isolation. In one within-person analysis,
32
 daily stress 
was not consistently associated with GI symptoms, which is in line with our conclusions. Labus et al,
33
 
although not using within-person correlations, showed that GI symptom severity was related more 
strongly to GI-specific anxiety than to other psychological IBS features. Wiklund et al
34
 found GI 
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symptom severity to be more strongly correlated with quality of life than with general anxiety and 
depression. Lackner et al
11
 presented similar results, albeit with different questionnaires. Wilpart et 
al
12
 focused on coping resources, and found statistically significant associations between coping and 
all other tested IBS features. Finally, in the present study, quality of life was in the centre of the 
network, suggesting that quality of life in IBS is influenced by the totality of IBS features rather than 
GI symptom severity alone. It has been mentioned before that multiple independent predictors exist 
of reduced quality of life in IBS, i.e. both intestinal symptoms and psychological factors.
35
 
 
Symptom evolution and subgroups thereof 
Three classes of GI symptom severity evolution emerged, and four classes for quality of life. The 
classes differed chiefly by overall symptom severity (p<0.001), but, to a lesser extent, also by linear 
slope (p=0.002). The class of IBS patients with a high mean GI symptom severity had a high mean GI 
symptom severity in all follow-up years, and did on average not improve. That class was formed by 
relatively young women, having unselected rather than PI-IBS as well as high psychological symptom 
scores at baseline. It has been found previously that IBS is somewhat more prevalent with young 
age
36
 and that PI-IBS patients have a slightly better long-term prognosis.
37
 Moreover, it has been 
previously reported that a low rectal pain threshold is cross-sectionally associated with high GI 
symptom severity,
24
 which is in agreement with our results. From our results one may theorise that 
the more symptomatic IBS patients are more refractory to treatment or sensitive to medication side-
effects, and such patients require a specific management strategy. Few studies, however, have 
specifically portrayed the longitudinal development of IBS features, and those studies usually relied 
on two data points, so that development trajectories cannot be inferred.  
 
Prediction of rank order changes in GI symptom severity and quality of life 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
GI-specific anxiety predicted an increase in GI symptom severity and a decrease in quality of life one 
year later. This brings forward GI-specific anxiety as factor of interest when assessing the severity of 
GI symptoms and predicting changes over time. No statistically significant predictive relations were 
found for the other psychological IBS features. Nevertheless, general anxiety and depression were 
from the HADS, which queries one's state over the past seven days, and as such may not reflect a 
general anxiety disorder or trait anxiety. It is still possible that trait anxiety can predict lack of 
improvement in GI-specific anxiety, GI symptom severity, and quality of life. Few studies investigated 
predictive relations between IBS features, although depression has been mentioned as negative 
predictor of treatment effect.
38
 Labus et al
33
 performed path analysis on IBS features, and found GI-
specific anxiety to mediate the relation between psychological distress and GI symptom severity, 
although that analysis was cross-sectional and results are therefore difficult to compare with ours. 
Since GI-specific anxiety predicted within-person changes in GI symptom severity and quality of life, 
it may be considered a key treatment target in IBS patients. Ljótsson et al
39
 have recently shown in 
well-controlled clinical trials on internet-based cognitive behaviour therapy (CBT) that exposure and 
mindfulness components effectively reduce IBS symptoms and GI-specific anxiety, while improving 
quality of life. More specifically, they demonstrated that the effect on GI symptoms is mediated by a 
decrease in GI-specific anxiety,
40
 supporting the present study in its notion that changes in GI-specific 
anxiety predict changes in IBS symptom severity. Further, they also confirm that GI-specific anxiety is 
treatable using CBT, which should therefore be considered a first-line treatment option in IBS 
patients with GI-specific anxiety. By contrast, IBS patients presenting with general anxiety or 
depression may require a different approach. More specifically, co-morbid anxiety and depressive 
disorders should obviously warrant referral to a mental health professional for 
psychopharmacological and/or or psychotherapeutic treatment, but based on our results, such 
treatment may have less impact on GI symptom severity or IBS-specific quality of life. The present 
study and its clinical implications thus highlight the heterogeneity amongst IBS patients and hence 
the potential need for individually tailored treatment. 
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One strength of the present study is that we use a longitudinal IBS cohort with six measurement 
points, allowing to monitor various IBS features over time. Furthermore, we reported within-person, 
rather than between-person correlations, giving a better understanding of the true relation between 
the IBS features. The study also has limitations. We had one data point per year, so that we could not 
quantify fluctuations within the year. Besides, latent class growth analyses are highly sensitive, 
introducing a risk for chance-based classifications.
41
 It also cannot be stated that individual patients 
belong to a specific class, as class assignment is based on probability. To investigate symptom 
patterns of individual IBS patients and short-term fluctuations, different symptom monitoring 
approaches are needed, such as symptom diaries with a higher sampling frequency, although these 
will inherently be limited to shorter follow-up periods. Having information about treatment or 
medication side-effects would also have been desirable, in order to understand better why one class 
of patients does not improve over time. Furthermore, it is possible that patients are more likely to 
accept to be part of a study when they are in a symptomatic phase, thereby influencing the pattern 
of symptom evolution. Finally, the drop-out rate was rather high, although participants who 
completed or dropped out of the study did not differ on any baseline IBS feature. 
In summary, we show that GI symptom severity can be described by different classes of evolution, 
and that these classes are associated with multiple baseline IBS-related features, such as 
psychological comorbidity, rectal sensitivity, post-infectious origin of IBS, age, and sex. GI symptom 
severity is strongly related to GI-specific anxiety, but not to general anxiety, depression, or coping 
resources, which are likely to stand in relative isolation from GI symptom severity. Finally, GI-specific 
anxiety can predict a change in GI symptom severity and quality of life one year later. Clinicians are 
recommended to be particularly attentive to GI-specific anxiety in IBS patients and refer patients for 
treatment targeting this key IBS feature, such as CBT. 
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Figure captions 
Figure 1: Network of longitudinal, within-person correlations (r) between IBS features. Correlations 
of |r|<0.3 were made invisible for graphical purposes, but do influence the network. *: p<0.005. 
Figure 2: Trajectory classes of GI symptom severity (left) and quality of life (right). Whiskers are 
minimum and maximum values. GI symptom severity: higher is worse; quality of life: higher is better. 
Figure 3: Random-intercept cross-lagged panel models for GI symptom severity and quality of life. 
Diagonal paths between variables represent predictive relations. Non-statistically significant paths 
were made invisible for graphical purposes. Values are standardised coefficients. 
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Tables 
Table 1: Descriptive statistics of selected IBS features in the cohort. Values are means ± SD or counts. 
 Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 
NNON-MISSING (≈) 212 194 163 124 105 107 
M
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GI symptom severity 3.1 ± 0.8 2.9 ± 0.9 2.9 ± 1.0 2.8 ± 0.9 2.7 ± 0.9 2.7 ± 0.8 
Quality of life 66 ± 17 73 ± 16 75 ± 17 77 ± 15 79 ± 15 78 ± 16 
GI-specific anxiety 34 ± 17 29 ± 17 25 ± 16 24 ± 16 25 ± 16 25 ± 16 
Coping resources 175 ± 22 169 ± 24 171 ± 24 171 ± 25 172 ± 25 172 ± 25 
General anxiety 6.9 ± 4.3 6.1 ± 4.0 5.6 ± 4.0 5.5 ± 4.6 5.3 ± 4.0 5.6 ± 3.8 
Depression 4.6 ± 3.6 4.1 ± 3.7 3.8 ± 3.6 3.9 ± 3.9 3.6 ± 3.6 3.9 ± 3.4 
 
 
Table 2: Correlation matrix of IBS features, with both within-person and between-person correlations. *: p<0.05, **: 
p<0.001. 
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GI symptom severity  -0.56
**
 0.47
**
 0.22
**
 0.26
**
 -0.15
*
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Quality of life -0.66
**
  -0.64
**
 -0.30
**
 -0.39
**
 0.20
*
 
GI-specific anxiety 0.56
**
 -0.72
**
  0.34
**
 0.34
**
 -0.14
*
 
General anxiety 0.34
**
 -0.46
**
 0.43
**
  0.49
**
 -0.28
**
 
Depression 0.29
**
 -0.50
**
 0.38
**
 0.64
**
  -0.40
**
 
Coping resources -0.18
*
 0.34
**
 -0.32
**
 -0.54
**
 -0.63
**
   
 Between-person correlations   
 
 
Table 3: Baseline descriptive statistics of the latent growth classes. 
 GI symptom severity Quality of life 
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 Low Mid High P Low Mid 1 Mid 2 High P 
N 59 119 36  24 43 73 67  
Intercept 2.3 3.4 3.8 <.001 32 47 61 78 <.001 
Slope -0.3 -0.1 0.1 .002 2 5 7 6 .24 
Quadratic coefficient 0.05 0.01 -0.02 .03 -0.18 -0.76 -0.80 -0.66 .70 
Age (years) 44 ±13 41 ±14 36 ±11 .004 38 ±12 40 ±15 42 ±15 41 ±12 .41 
Female (%) 31 (53) 86 (72) 31 (86) .001 18 (75) 31 (72) 54 (74) 43 (64) .52 
IBS-C (%) 11 (19) 23 (20) 7 (20) 
.19 
4 (17) 8 (19) 12 (17) 15 (23) 
.78 IBS-D (%) 29 (50) 47 (40) 9 (26) 9 (39) 15 (36) 28 (39) 30 (45) 
IBS-A (%) 18 (31) 47 (40) 19 (54) 10 (43) 19 (45) 32 (44) 21 (32) 
PI-IBS (%) 7 (27) 6 (9) 1 (5) .04 1 (7) 3 (16) 3 (7) 6 (21) .28 
IBS duration (years) 11 ±7 11 ±8 10 ±5 .78 10 ±5 10 ±5 10 ±7 11 ±7 .63 
Rectal pain threshold 
(mmHg) 
41 ±12 36 ±13 31 ±12 .002 30 ±10 32 ±13 36 ±12 40 ±15 .002 
Accelerated transit (%)  6 (24) 6 (10) 7 (29) 
.17 
5 (26) 3 (12) 6 (15) 5 (20) 
.56 
Delayed transit (%) 3 (12) 14 (23) 5 (21) 6 (32) 4 (16) 8 (20) 4 (16) 
GI symptom severity 2.4 ±0.6 3.2 ±0.6 3.9 ±0.6 <.001 3.7 ±0.6 3.6 ±0.7 3.2 ±0.7 2.7 ±0.7 <.001 
Quality of life 74 ±15 58 ±18 41 ±19 <.001 30 ±10 46 ±13 60 ±14 77 ±13 <.001 
GI-specific anxiety 23 ±14 34 ±16 44 ±14 <.001 50 ±13 40 ±13 33 ±16 22 ±12 <.001 
General anxiety 5 ±4 7 ±4 9 ±5 <.001 10 ±5 8 ±4 7 ±4 4 ±3 <.001 
Depression 3 ±4 5 ±3 7 ±4 <.001 9 ±3 5 ±3 4 ±3 3 ±3 <.001 
Coping resources 177 ±23 177 ±20 171 ±23 .29 167 ±20 174 ±23 175 ±22 181 ±19 .01 
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Supplementary Figure 1: Theoretical example of a relation between X and Y, with six participants and 
five data points per participant. Here, the regular Pearson correlation (thick line) is very different 
from the within-person correlation (thin lines). This discrepancy is an example of Simpson's paradox. 
 
 
Supplementary Table 1: Comparison of drop-outs and non-drop-outs. For drop-outs, the last available value was used. 
 Non-drop-out Drop-out P-value 
GI symptom severity 2.9 ± 0.9 3.0 ± 1.0 0.69 
Quality of life 69 ± 20 64 ± 23 0.33 
GI-specific anxiety 28 ± 17 29 ± 19 0.70 
Coping resources 169 ± 24 174 ± 24 0.32 
General anxiety 5.7 ± 4.1 6.4 ± 4.6 0.46 
Depression 4.1 ± 3.7 4.1 ± 3.8 0.98 
 
